Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
1 finding from 1 review
Number of participants experiencing an attacka · people with familial Mediterranean fever
Rilonacept showed no clear difference in number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review
Duration of attacksa · people with familial Mediterranean fever
1 finding from 1 review
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
Functional disability at 3 months ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Health‐related quality of life ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of success Not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · acute gout
Rilonacept showed no clear difference in adverse events ‐ study withdrawals due to adverse events compared with indomethacin (low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · acute gout
Rilonacept showed no clear difference in adverse events ‐ participants with at least 1 adverse event compared with indomethacin (low certainty).
1 finding from 1 review
Pain ‐ change from baseline to 24 to 72 hours Assessed on numerical rating scale (0 = no pain; 10 = extreme pain) · acute gout
1 finding from 1 review
Inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review